Upgrade to PyroMark Q24 Advanced

Advance your Pyrosequencing analyses
  • Main Image Navi
PyroMark Q24 Advanced features advanced technology, software, and chemistry to provide even better real-time sequence‑­­based detection and quantification than before. With longer sequencing runs and higher accuracy, the PyroMark Q24 Advanced system is highly suited for analyzing any kind of sequence variation, particularly DNA methylation at CpG or CpN sites, complex mutations, or for de novo sequencing applications such as microbial typing. Take advantage of these new features by upgrading your existing PyroMark Q24 system to PyroMark Q24 Advanced. Learn more at the PyroMark Q24 Advanced product page.

Non-small cell lung cancer
About the therascreen EGFR test
Understanding insurance coverage

 

What is non-small cell lung cancer?

  • NSCLC is 1 of 2 major types of lung cancer, which  accounts for 85%-90% of lung cancers

The two major types of lung cancer grow and spread in different ways and may have different treatment options, so a distinction between these two types is important. Among treatment options for patients diagnosed with NSCLC, new treatments, called targeted therapies are now available and approved. However, studies have found that only some patients benefit from certain targeted therapies. A test can find changes in the EGFR gene that make it more likely that a person’s lung cancer will respond to treatment with an EGFR inhibitor like either GILOTRIF (afatinib) or IRESSA (gefitinib). Determining who might benefit could save some people from trying treatments that are unlikely to work for them.

Back to topAbout the therascreen EGFR test

The therascreen EGFR test reliably detects mutations, or changes, in the EGFR gene within your NSCLC tumor. The status of the EGFR gene helps your oncologist determine the best method of treatment.

  • If your EGFR gene status is not normal, then you may benefit from either GILOTRIF (afatinib) or IRESSA (gefitinib) treatment
  • If your EGFR gene is normal, your doctor will determine an appropriate alternative treatment

If you, or someone you know, have been diagnosed with NSCLC, ask your oncologist about the FDA approved EGFR test for patients with NSCLC, the therascreen EGFR test.

Back to topUnderstanding insurance coverage

The therascreen EGFR test:

  • Is FDA-approved for the detection of mutations in the EGFR gene
  • Helps identify which patients might be helped by either GILOTRIF (afatinib) or IRESSA (gefitinib) treatment

Public and private payers endorse the value of EGFR testing with strong coverage policies for approved indications.

QIAGEN has a broad portfolio of companion diagnostic products in development.

 


Top products
4
Analysis software for upgrading PyroMark Q24 systems to PyroMark Q24 Advanced
Show details
See products
Blue boxes - generic image
For advanced methylation and mutation quantification in long sequence runs using Pyrosequencing
Show details
See products
Blue boxes - generic image
For optimal sample preparation and Pyrosequencing analysis using the PyroMark Q24 Advanced
Show details
See products
For advanced methylation and mutation quantification in long sequence runs using Pyrosequencing
Show details
See products
Resources

You are not authorized to download the resource

Instrument User Manuals
1
Kit Handbooks
1
Operating Software
1
Files for upgrading existing PyroMark Q24 instruments to firmware 1.5.6903
Show details
Download Files
1
Files for upgrading existing PyroMark Q24 instruments to firmware 1.5.6903
Show details
Brochures & Guides
1
PyroMark Q24 Advanced — for advanced methylation and mutation quantification in long sequence runs
Show details